Press Release

ONCOLYS BIOPHARMA INC. (TSE Mothers: 4588)

1 December 2015

**OBP-401 (TelomeScan™) ADOPTED IN CLINICAL TRIALS FOR THE DEVELOPMENT OF NOVEL MOLECULAR TARGETED ANTI-CANCER AGENTS**

**Tokyo, JAPAN:** Oncolys BioPharma is pleased to announce that its OBP-401 (TelomeScan™), which is under development as a test agent to detect blood circulating cancer cells (CTC), is decided to be adopted for clinical trials for the anti-cancer drug development led by the US biotech company Deciphera Pharmaceuticals, LLC (Waltham, MA, USA), on December 1, 2015.

Oncolys has been providing OBP-401 and OBP-1101 to Deciphera for the validation purpose in clinical trials for the development of novel molecular targeted anti-cancer agents since July this year. Based on recent successful verification results, Deciphera decided to use OBP-401 for the secondary efficacy endpoint measurement in the above-said clinical trials where Oncolys and Deciphera will share the related data. In this connection, there is no impact expected on Oncolys’ earnings this fiscal year.

Oncolys is determined to make its best efforts to contribute to solve problems faced by patients and doctors in the medical settings, by promoting more efficient drug development by accelerating the validation of new drug development. In addition to its amicable business relations with Deciphera, Oncolys will continue to expand its marketing network for diagnostic business further, actively communicating pharmaceutical companies and research institutions globally.

**About Deciphera Pharmaceuticals, LLC.**

Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera’s unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera’s business strategy is to advance its drug candidates for genetically defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.
This English translation is a summary of the Japanese original for English readers' convenience only. If there are any differences between this translation and the Japanese original, the Japanese original supersedes this translation.

**About OBP-401 (TelomeScan™):**
TelomeScan™ is a telomerase-specific replication-competent adenovirus vector developed by Oncolys and originally invented by Okayama University, and is containing green fluorescent protein (GFP) gene, which is the research theme of Dr. Osamu Shimomura, the 2008 Nobel Prize winner in Chemistry and a senior scientist emeritus and corporation member at the Marine Biological Laboratory (MBL), Boston University (U.S.). When TelomeScan™ is incubated with cancer cells, it will specifically replicate in those cells, resulting in production of GFP which makes tumor cells be visualized with green fluorescence. We are aiming to develop and commercialize TelomeScan™ as the first GFP-using diagnostic agent in the world.

**About Oncolys BioPharma Inc.:**
Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, OBP-301 (Telomelysin™), is based on replication-competent oncolytic virus, and is being tested in Phase I/II clinical trial in Asia, for various solid tumors. A novel cancer diagnostic product, OBP-401 (TelomeScan), is expected to be effective in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Censavudine) for infectious diseases, which has completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS. OBP-601 is a novel NRTI with highly promising safety and resistance profiles. For more additional information, please visit www.oncolys.com

**Forward-looking statements**
This release may contain forward-looking statements based on current assumptions and forecasts made by Oncolys BioPharma's management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Oncolys' public reports which are available on the Oncolys BioPharma’s website at http://www.oncolys.com/. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

**Oncolys BioPharma Inc.**

<table>
<thead>
<tr>
<th>Mie Yamazaki</th>
</tr>
</thead>
<tbody>
<tr>
<td>IR &amp; Corporate Communications</td>
</tr>
<tr>
<td>Tel: +81 (0) 5472 1578</td>
</tr>
<tr>
<td>Email: <a href="mailto:yamazaki@oncolys.com">yamazaki@oncolys.com</a></td>
</tr>
</tbody>
</table>